CD20 antibody as first treatment for marginal zone lymphoma
Part of Cancer clinical trials.
This study tests whether giving a CD20 monoclonal antibody (a type of immunotherapy that targets lymphoma cells) as the very first treatment helps people with marginal zone lymphoma. The goal is to control the lymphoma and improve symptoms without using stronger chemotherapy first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called marginal zone lymphoma (MZL), confirmed by a biopsy.
- You are 18 years or older.
- Your lymphoma needs treatment — for example, it is growing, causing symptoms, or affecting your blood counts.
- You have not already had systemic treatments (like chemotherapy or immunotherapy) for your lymphoma.
- You are generally in good health (can do most daily activities, life expectancy over 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, rituximab and venetoclax, as a first treatment for marginal zone lymphoma that has not been treated before. The goal is to see if this drug pair is safe and effective.
This trial tests a new combination of two drugs for people with a type of lymphoma called marginal zone lymphoma who have not had prior systemic treatment. It aims to see if the combination can shrink or control the cancer and improve quality of life.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for marginal zone lymphoma that has spread or is advanced. The goal is to see if this combination is effective and safe for patients who have not had prior treatment.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
Hear when a new MZL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.